European Journal of Heart Failure最新文献

{"title":"Prognostic significance of somatic mutations in myeloid cells of men with chronic heart failure - interaction between loss of Y chromosome and clonal haematopoiesis.","authors":"Sebastian Cremer, Moritz von Scheidt, Klara Kirschbaum, Lukas Tombor, Silvia Mas-Peiro, Wesley Abplanalp, Tina Rasper, Akshay Ware, Andrin Schuff, Alexander Berkowitsch, Johannes Krefting, David Leistner, Heribert Schunkert, Thimoteus Speer, Stefanie Dimmeler, Andreas Michael Zeiher","doi":"10.1002/ejhf.3778","DOIUrl":"https://doi.org/10.1002/ejhf.3778","url":null,"abstract":"<p><strong>Aims: </strong>Age-associated clonal haematopoiesis of indeterminate potential (CHIP) has been linked to increased incidence and worse prognosis of chronic heart failure (CHF). CHIP arises from somatic mutations in haematopoietic stem and progenitor cells. Mosaic loss of Y chromosome (LOY), the most common somatic mutation in male blood cells, increases with age, drives clonal expansion of myeloid cells, and has been experimentally associated with cardiac fibrosis and heart failure in mice. However, its prognostic value and interplay with CHIP in CHF patients remain unclear.</p><p><strong>Methods and results: </strong>We analysed 781 male CHF patients across the full spectrum of left ventricular ejection fraction to assess the prevalence and prognostic relevance of LOY and the two most common CHIP-driver mutations, DNMT3A and TET2. Both LOY and CHIP mutations increased with age and co-occurred in 27.1% of men >70 years. LOY independently predicted all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF). The co-occurrence of LOY and DNMT3A/TET2 mutations further increased mortality among CHIP carriers. This detrimental prognostic effect of LOY was confirmed in a validation cohort of HFrEF patients. Single-cell RNA sequencing of peripheral blood mononuclear cells from HFrEF patients with ischaemic heart failure revealed elevated pro-fibrotic signalling in LOY monocytes, characterized by increased inflammatory and remodelling markers (S100A8, TLR2, CLEC4D) and decreased expression of transforming growth factor-β inhibitors (SMAD7, TGIF2). In patients with both LOY and DNMT3A mutations, monocytes showed enhanced pro-inflammatory gene expression, including alarmins (S100A8, HMGB2) and interferon-related genes (IFNGR1, TRIM56, CD84).</p><p><strong>Conclusions: </strong>Somatic mutations in blood cells-particularly LOY-are associated with increased mortality in male CHF patients, with LOY emerging as an independent prognostic marker.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence fully automated analysis of handheld echocardiography in real-world patients with suspected heart failure.","authors":"Ross T Campbell,Mark C Petrie,Kieran F Docherty,Katriona J M Brooksbank,Gemma McKinley,Caroline Haig,Alex McConnachie,Carolyn S P Lam,Carly Adamson,Elaine Butler,James P Curtain,Nick Hartshorne-Evans,Fraser J Graham,Helen Hainey,John Jarvie,Matthew M Y Lee,Leeanne Macklin,Kenneth Mangion,Aimee McCoubrey,Kirsty McDowell,Aileen McIntyre,Sabrina Nordin,Joanna Osmanska,Pierpaolo Pellicori,Joanne Simpson,Piotr Sonecki,Karen Taylor,Daniel Taylor-Sweet,Pamela Turnbull,Paul Welsh,John J V McMurray,Clare L Murphy,David J Lowe","doi":"10.1002/ejhf.3783","DOIUrl":"https://doi.org/10.1002/ejhf.3783","url":null,"abstract":"AIMSEchocardiography is a rate-limiting step in the timely diagnosis of heart failure (HF). Automated reporting of echocardiograms has the potential to streamline workflow. The aim of this study was to test the diagnostic accuracy of fully automated artificial intelligence (AI) analysis of images acquired using handheld echocardiography and its interchangeability with expert human-analysed cart-based echocardiograms in a real-world cohort with suspected HF.METHODS AND RESULTSIn this multicentre, prospective, observational study, patients with suspected HF had two echocardiograms: one handheld portable and one cart-based scan. Both echocardiograms were analysed using fully automated AI software and by human expert sonographers. The primary endpoint was the diagnostic accuracy of AI-automated analysis of handheld echocardiography to detect left ventricular ejection fraction (LVEF) ≤40%. Other endpoints included the interchangeability (assessed using individual equivalence coefficient [IEC]), between AI-automated and human analysis of cart-based LVEF. A total of 867 patients participated. The AI-automated analysis produced an LVEF in 61% of the handheld scans and 77% of the cart-based scans, compared to 76% and 77% of human analyses of the handheld and cart-based scans, respectively. The AI-automated analysis of handheld echocardiography had a diagnostic accuracy of 0.93 (95% confidence interval [CI] 0.90, 0.95) for identifying LVEF ≤40% (compared to the human analysis of cart-based transthoracic echocardiography scans). AI-automated analysis of LVEF on handheld devices was interchangeable with cart-based LVEF reported by two expert humans (IEC -0.40, 95% CI -0.60, -0.16).CONCLUSIONSArtificial intelligence-automated analysis of handheld echocardiography had good diagnostic accuracy for detecting LVEF ≤40%. AI-automated analysis of LVEF of handheld scans was interchangeable with cart-based expert human analysis.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"105 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding the article ‘Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study’","authors":"Elapulli Sankaranarayanan Prakash","doi":"10.1002/ejhf.3790","DOIUrl":"https://doi.org/10.1002/ejhf.3790","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"90 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144685142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond pharmacotherapy: Addressing system‐level barriers in women's heart failure care. Letter regarding the article ‘Sex‐based differences in heart failure management and outcomes: Insights from the French‐DataHF cohort’","authors":"Haiyan Zhang, Wenxin Gao","doi":"10.1002/ejhf.3791","DOIUrl":"https://doi.org/10.1002/ejhf.3791","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"143 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144685141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘What's new in heart failure? May–June 2024’, ‘What's new in heart failure? June–July 2024’, ‘What's new in heart failure? August–September 2024’, ‘The month in heart failure! September 2024’, ‘What's new in heart failure? October 2024’, ‘What's new in heart failure? November 2024’, ‘What's new in heart failure? December 2024’, ‘What's new in heart failure? January 2025’, ‘What's new in heart failure? February 2025’, ‘What's new in heart failure? March 2025’, ‘What's new in heart failure? April 2025’, ‘What's new in heart failure? May 2025’","authors":"","doi":"10.1002/ejhf.3776","DOIUrl":"https://doi.org/10.1002/ejhf.3776","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"52 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to 'Beyond pharmacotherapy: Addressing system-level barriers in women's heart failure care'.","authors":"Guillaume Baudry,Ouarda Pereira,François Roubille,Nicolas Girerd","doi":"10.1002/ejhf.3793","DOIUrl":"https://doi.org/10.1002/ejhf.3793","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"1 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter regarding the article 'Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study'.","authors":"Jan Biegus,Piotr Ponikowski","doi":"10.1002/ejhf.3792","DOIUrl":"https://doi.org/10.1002/ejhf.3792","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"89 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure","authors":"Tibor Kempf, Welf Geller, Jan Fuge, Mircea‐Andrei Sandu, Marius M. Hoeper, Roman Pfister, Sascha Macherey‐Meyer, Stefan Störk, Daniel Scheiber, Jürgen Bogoviku, Jörn Tongers, Tarek Bekfani, Christoph Schindler, Dominik Berliner, Udo Bavendiek, Johann Bauersachs","doi":"10.1002/ejhf.3789","DOIUrl":"https://doi.org/10.1002/ejhf.3789","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"675 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144677455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to ‘Is sodium chloride supplementation ready for clinical practice in acute heart failure?’","authors":"Jan Biegus, Robert Zymliński, Piotr Ponikowski","doi":"10.1002/ejhf.3773","DOIUrl":"https://doi.org/10.1002/ejhf.3773","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"51 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144677457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of canagliflozin on heart stress and outcomes: Pooled insights from CREDENCE and CANVAS.","authors":"Antoni Bayes-Genis,Anping Cai,Yuxi Liu,Ambarish Pandey,Rodica Pop-Busui,Michael Hansen,James L Januzzi","doi":"10.1002/ejhf.3786","DOIUrl":"https://doi.org/10.1002/ejhf.3786","url":null,"abstract":"AIMSIn individuals with type 2 diabetes with cardio-renal disease but no known heart failure (HF), elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of heart stress, signals higher risk of HF and cardio-kidney complications. This analysis assesses canagliflozin impact on heart stress and outcomes using age-adjusted NT-proBNP thresholds from two major trials.METHODS AND RESULTSThis analysis included 5281 participants from the CANVAS and CREDENCE trials without HF at baseline. NT-proBNP was measured at baseline and year 1, with heart stress defined using age-adjusted NT-proBNP thresholds. Outcomes included a primary composite (end-stage kidney disease, doubling of serum creatinine, kidney or cardiovascular death), kidney composite, HF hospitalization, cardiovascular death, all-cause death, and HF hospitalization or cardiovascular death composite. Multivariable Cox models assessed heart stress, outcomes, and canagliflozin effects. At baseline, 45% of participants had heart stress. Heart stress independently predicted increased risks for all outcomes, with the highest risks in those with persistent or rising NT-proBNP at baseline and year 1. Rising NT-proBNP by year 1 was associated with higher risk as well. Canagliflozin significantly reduced risks in individuals with heart stress, including the primary composite (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.62-0.84), kidney composite (HR 0.65, 95% CI 0.53-0.79), and HF hospitalization (HR 0.68, 95% CI 0.54-0.85). Benefits were less pronounced in those without heart stress.CONCLUSIONSAge-adjusted NT-proBNP thresholds effectively predict cardio-kidney events in at-risk type 2 diabetes individuals without HF. Canagliflozin offers strong cardiovascular and kidney protection, with the greatest benefits in those with heart stress, emphasizing the need for early identification and intervention.CLINICAL TRIAL REGISTRATIONSCANVAS (NCT01032629), CREDENCE (NCT02065791).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"13 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}